Servier will present updated three-year FIREFLY-1 data on OJEMDA (tovorafenib) and caregiver insights at ISPNO 2026, reinforcing its role in pediatric neuro-oncology.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Servier will present new long-term clinical data on OJEMDA (tovorafenib) and real-world caregiver insights at the 22nd International Symposium on Pediatric Neuro-Oncology (ISPNO 2026), taking place from June 28 to July 1 in Sydney, Australia. The presentations reinforce the company’s growing presence in neuro-oncology following its acquisition of Day One Biopharmaceuticals, the original developer of OJEMDA.
The meeting will feature two oral presentations based on updated three-year follow-up results from the pivotal Phase 2 FIREFLY-1 trial (NCT04775485) evaluating OJEMDA in children with relapsed or refractory pediatric low-grade glioma (pLGG) harboring BRAF alterations. A third presentation will report findings from a U.S. caregiver survey examining physician-family communication during pLGG diagnosis and early treatment planning.
Long-Term FIREFLY-1 Data
One oral presentation will focus on growth outcomes after treatment discontinuation. Investigators found that most children who experienced reduced growth velocity while receiving OJEMDA showed recovery in growth after stopping therapy. The analysis provides additional long-term safety evidence for a therapy intended for children who often require prolonged treatment.
A second analysis will examine how previous therapies influenced treatment outcomes. The updated three-year data showed that OJEMDA produced clinical benefit across different lines of therapy, with a trend toward longer-lasting responses in patients who had not previously received a MAPK inhibitor. These findings may guide treatment sequencing for BRAF-altered pLGG.
About OJEMDA and Pediatric Low-Grade Glioma
OJEMDA (tovorafenib) is an oral type II RAF kinase inhibitor that targets mutant BRAF V600 as well as wild-type BRAF and CRAF kinases. In the United States, it is approved under the FDA’s accelerated approval pathway for patients aged six months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or BRAF V600 mutation. Continued approval depends on confirmation of clinical benefit in ongoing studies.
Pediatric low-grade glioma is the most common brain tumor in children. More than half of cases carry BRAF alterations that drive tumor growth. Although survival is generally favorable, many children experience recurrent disease requiring multiple rounds of treatment, leading to cumulative neurological, developmental, endocrine, and visual complications.
Caregiver Survey Highlights Communication Gaps
Servier will also present results from a survey of caregivers of children with pLGG in the United States. The survey explored how physicians communicated the diagnosis, treatment options, and expected outcomes during initial consultations.
The findings identified both effective and suboptimal communication practices. Caregivers reported opportunities to improve clarity, strengthen trust between healthcare providers and families, and better prepare parents for treatment decisions during the early stages of care.
Clinical Implications
Elly Barry, MD, Chief Medical Officer of Day One Biopharmaceuticals, now part of Servier Group, said the new analyses continue to strengthen the evidence supporting OJEMDA in relapsed or refractory pediatric low-grade glioma. She noted that the long-term clinical findings, together with caregiver experience data, reflect Servier’s commitment to improving outcomes for both patients and their families.
The three-year FIREFLY-1 analyses extend the evidence supporting OJEMDA’s long-term safety and clinical activity in BRAF-altered pediatric low-grade glioma. As confirmatory studies continue, the updated data may further support the therapy’s role as a treatment option for children with relapsed or refractory disease while informing future standards of care in pediatric neuro-oncology.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.